CJC No Dac: 5mg Ipamorelin: 5mg BLEND

Research Dosing

When scientists first discovered the potential of CJC-1295 (often marketed as "CJC No DAC") and Ipamorelin, they were intrigued by how these peptides could synergistically enhance growth hormone release. Early laboratory work involved micro-doses ranging from 0.1 mg to 2 mg per injection in animal models, with researchers monitoring plasma growth-hormone levels every 30 minutes post-administration. The data suggested that even low doses produced measurable spikes in GH secretion, but the magnitude of response increased proportionally with the dose until a plateau was reached around 5 mg for each peptide. Subsequent human trials—although limited due to regulatory constraints—used similar dosing ranges and found that a single 5 mg injection could elevate GH levels by up to 15-20 ng/mL within an hour, lasting for several hours thereafter. These findings guided the formulation of a balanced blend, where equal parts of CJC No DAC and Ipamorelin are combined to maximize growth hormone stimulation while mitigating potential side effects.

CJC No Dac: 5mg/Ipamorelin: 5mg BLEND

The "5 mg / 5 mg" blend is designed for individuals seeking a robust yet controlled increase in endogenous growth hormone production. CJC-1295 without the drug-affinity component (DAC) remains a long-acting peptide, binding to growth hormone-releasing hormone receptors with high affinity and prolonging GH release over 24–48 hours. Ipamorelin, on the other hand, is a selective ghrelin receptor agonist that triggers an acute surge in GH secretion. By combining both at equal concentrations, the blend offers a dual mechanism: an immediate spike from Ipamorelin followed by sustained elevation from CJC No DAC. Users typically reconstitute each peptide separately with sterile water or saline to a concentration of 1 mg/mL, then mix equal volumes (e.g., 5 mL of each) before injecting. This approach ensures that the final solution delivers 5 mg of each peptide per injection.

Dosing Guidelines (Blend)

The recommended schedule for the 5 mg/5 mg blend varies depending on the individual's goals, experience level, and tolerance. A common protocol is:

Beginners: 1–2 injections weekly. This allows the body to adapt while monitoring for any adverse reactions.

Intermediate users: 3–4 injections per week, spaced evenly (e.g., Monday, Wednesday, Friday). This maintains a more consistent GH baseline without overwhelming the system.

Advanced users or athletes: 5–6 injections per week, often at 12-hour intervals (morning and evening). This maximizes anabolic benefits but requires close monitoring of side effects.

Each injection should be administered subcutaneously, typically in the abdomen or thigh. The blend can also be split into two smaller doses (2.5 mg/2.5 mg) if a user prefers to reduce peak hormone spikes while still achieving overall benefit. It is essential to maintain proper hygiene and use sterile needles to avoid infections.

Possible Side Effects

While the CJC No DAC / Ipamorelin blend is generally well tolerated, users may experience:

Water retention: Mild swelling in extremities due to increased vasodilation.

Joint discomfort or stiffness: Particularly if GH levels rise rapidly; stretching and light activity can mitigate this.

Headaches or dizziness: Often related to transient changes in blood pressure.

Increased appetite: A natural consequence of ghrelin receptor activation, which may lead to weight gain if caloric intake isn’t adjusted.

Injection site reactions: Redness, itching, or mild inflammation.

These side effects are typically dose-dependent and tend to diminish with consistent use as the body adapts. In rare cases, elevated GH can affect glucose metabolism; monitoring blood sugar levels is advised for individuals with preexisting metabolic conditions.

Contraindications & Cautions

Certain populations should avoid using this blend or consult a healthcare professional before initiating therapy:

Pregnant or nursing women: Peptide effects on fetal development are not well studied.

Individuals with hormone-sensitive cancers (breast, prostate): Excess GH could potentially stimulate tumor growth.

People with uncontrolled diabetes or severe cardiovascular disease: The blend may alter glucose handling and blood pressure.

Those taking other growth-hormone-stimulating agents: Combining multiple stimulants can lead to unpredictable hormonal fluctuations.

Additionally, users should be mindful of potential interactions with medications that influence liver metabolism (e.g., certain statins) since peptides are cleared primarily through renal pathways. Maintaining a balanced diet, adequate hydration, and regular exercise can help offset some adverse effects.

Suggested Pairings (Stacking)

To enhance the benefits of the CJC No DAC / Ipamorelin blend, many practitioners stack complementary substances:

HGH Secretagogues: Other peptides such as Sermorelin or GHRP-6 can be added to create a "super-blend" that amplifies GH release. However, stacking multiple secretagogues increases the risk of side effects and should only be done under professional guidance.

Anabolic Steroids (for athletes): Combining with low-dose anabolic agents may accelerate muscle hypertrophy, though this practice carries significant legal and health risks.

Omega-3 Fatty Acids: Support vascular health and reduce inflammation that might accompany increased GH activity.

Vitamin D & Magnesium: These nutrients aid in muscle function and can mitigate cramps or joint stiffness often reported during high-GH periods.

When stacking, it is crucial to adjust dosing intervals so that peak hormone levels do not overlap excessively. A typical strategy is to inject the peptide blend first, followed by a secondary compound 2–4 hours later, allowing each agent’s effect to manifest independently.

By carefully following these guidelines and staying attentive to bodily responses, users can harness the full potential of the CJC No DAC / Ipamorelin 5 mg/5 mg blend while minimizing risks.